Journal
PHARMACOTHERAPY
Volume 41, Issue 1, Pages 44-58Publisher
WILEY
DOI: 10.1002/phar.2493
Keywords
BMI; immunotherapy; obesity; pharmacokinetics; transplant; underweight
Categories
Ask authors/readers for more resources
This review discusses the differences in pharmacokinetics in patients with body mass index extremes and how solid organ transplant recipients can address these differences, including management strategies and potential drug-drug interactions.
The pharmacokinetic profiles of medications are altered in overweight and underweight patients, but few studies have described these differences in patients with body mass index extremes. As solid organ transplant programs expand their candidate selection criteria to accommodate a growing population of patients with weight extremes, it has become imperative to understand and evaluate the impact weight extremes have on the pharmacokinetics of life-sustaining immunosuppression in this population. This review will describe pharmacokinetic and dosing considerations for weight extremes in solid organ transplant recipients, including changes following bariatric surgeries, non-pharmacologic and pharmacologic management strategies for weight loss and gain, and potential drug-drug interactions with popular weight management products.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available